Results 261 to 270 of about 262,938 (292)
Some of the next articles are maybe not open access.
The Lancet, 2009
Parkinson's disease is a common progressive bradykinetic disorder that can be accurately diagnosed. It is characterised by the presence of severe pars-compacta nigral-cell loss, and accumulation of aggregated alpha-synuclein in specific brain stem, spinal cord, and cortical regions. The main known risk factor is age.
Andrew J, Lees +2 more
openaire +2 more sources
Parkinson's disease is a common progressive bradykinetic disorder that can be accurately diagnosed. It is characterised by the presence of severe pars-compacta nigral-cell loss, and accumulation of aggregated alpha-synuclein in specific brain stem, spinal cord, and cortical regions. The main known risk factor is age.
Andrew J, Lees +2 more
openaire +2 more sources
European Journal of Neurology, 2019
Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 000 and 11–19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors.
R, Balestrino, A H V, Schapira
openaire +4 more sources
Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 000 and 11–19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors.
R, Balestrino, A H V, Schapira
openaire +4 more sources
2013
In advanced Parkinson's disease (PD), the emergence of symptoms refractory to conventional therapy poses therapeutic challenges. The success of deep brain stimulation (DBS) and advances in the understanding of the pathophysiology of PD have raised interest in noninvasive brain stimulation as an alternative therapeutic tool.
John C, Rothwell, Mark J, Edwards
openaire +4 more sources
In advanced Parkinson's disease (PD), the emergence of symptoms refractory to conventional therapy poses therapeutic challenges. The success of deep brain stimulation (DBS) and advances in the understanding of the pathophysiology of PD have raised interest in noninvasive brain stimulation as an alternative therapeutic tool.
John C, Rothwell, Mark J, Edwards
openaire +4 more sources
Inflammation and immune dysfunction in Parkinson disease
Nature Reviews Immunology, 2022Malú Gámez Tansey +2 more
exaly
Parkinson disease-associated cognitive impairment
Nature Reviews Disease Primers, 2021Dag Aarsland +2 more
exaly